HCW Biologics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.5M
- Price
- $1.56
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.64%
- Volume
- 30.7K
About
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
Quick stats
Shares outstanding2.2M
Computed float2.0M
Float / shares91.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001828673
Websitehttps://www.hcwbiologics.com
AI Summary
AI-generated1/22
minorbearishoffering
HCW Biologics Announces Pricing of $1.5 Million Private Placement
HCW Biologics priced a $1.5 million private placement of 903,614 units at $1.6599 per unit with an existing stockholder, with Maxim Group as sole placement agent.
Each unit contains one pre-funded warrant exercisable immediately at $0.0001 per share plus a common warrant at $1.66 per share, subject to stockholder approval under Nasdaq Rule 5635(d).
Proceeds will fund HCW9302 clinical trials, IND-enabling studies for HCW11-018b and HCW11-040, and general corporate purposes; the company must file a resale registration statement within 15 trading days of closing.
Red flags
- pre-funded warrants with $0.0001 exercise price mean immediate dilution at closing
- small raise relative to clinical-stage burn rate signals ongoing funding needs
- resale registration S-1 within 15 trading days adds overhang